Advertisement

FDA approves first pill to treat all forms of hepatitis C

By Associated Press  |  June 28, 2016

Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.

When not-for-profit leaders serve on corporate boards

By Bob Herman  |  June 04, 2016

Corporate CEOs, attorneys, real estate moguls and other business leaders routinely serve on the boards of not-for-profit hospitals, systems and insurers. But some top executives at not-for-profit healthcare organizations also hold board seats at some of the largest publicly traded companies in the...

Gilead paying up to $1.2B for Nimbus unit, drug, technology

By Associated Press  |  April 04, 2016

Biologic drugmaker Gilead Sciences is buying a subsidiary of Nimbus Therapeutics and its experimental medicine for an increasingly prevalent metabolic disorder that causes dangerous fat buildup in the liver.

Editorial: Keep CMS' value-based pay off my Medicare drugs!

Editorial: Keep CMS' value-based pay off my Medicare drugs!

By Merrill Goozner  |  March 12, 2016

Everyone is in favor of value-based reimbursement in healthcare, right? If you're still wearing those rose-colored glasses, take a closer look at last week's reaction to Medicare's proposal to test new ways of paying for drugs administered in physician offices and hospital outpatient departments.

Senate panel votes to add Zika to controversial FDA review voucher program

By Steven Ross Johnson  |  March 09, 2016

Members of the Senate's health committee voted Wednesday in favor of a bill that would add Zika to the list of 21 neglected, rare tropical diseases eligible for a voucher to fast-track approval by the FDA. Critics of the program say the FDA needs to prevent it from being exploited by drugmakers.

Gilead CEO resigns amid pricing scrutiny

By Adam Rubenfire  |  February 01, 2016

Gilead Sciences, the Foster City, Calif.-based drugmaker under pressure for its hepatitis C drug pricing, announced late last week that longtime CEO John Martin will step down from that role, becoming executive chairman of the company.

High drug prices will be a big political issue in 2016

High drug prices will be a big political issue in 2016

By Steven Ross Johnson  |  January 01, 2016

High prescription drug prices will be a top-tier political issue in 2016 as the expected introduction of many expensive specialty medications to treat chronic conditions threatens to drive up healthcare spending.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.